Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Open access
Roper, Nitin, Brown, Anna-Leigh, Wei, Jun S., Pack, Svetlana, Trindade, Christopher, Kim, Chul, Restifo, Olivia, Gao, Shaojian, Sindiri, Sivasish, Mehrabadi, Farid, El Meskini, Rajaa, Ohler, Zoe Weaver, Maity, Tapan K., Venugopalan, Abhilash, Cultraro, Constance M., Akoth, Elizabeth, Padiernos, Emerson, Chen, Haobin, Kesarwala, Aparna, Smart, DeeDee K., Nilubol, Naris, Rajan, Arun, Piotrowska, Zofia, Xi, Liqiang, Raffeld, Mark, Panchenko, Anna R., Sahinalp, Cenk, Hewitt, Stephen, Hoang, Chuong D., Khan, Javed, Guha, Udayan · 2020 · Cell Reports Medicine

Abstract

Clonal evolution of osimertinib-resistance mechanisms in EGFR mutant lung adenocarcinoma is poorly understood. Using multi-region whole-exome and RNA sequencing of prospectively collected pre- and post-osimertinib-resistant tumors, including at rapid autopsies, we identify a likely mechanism driving osimertinib resistance in all patients analyzed. The majority of patients acquire two or more resistance mechanisms either concurrently or in temporal sequence. Focal copy-number amplifications occur subclonally and are spatially and temporally separated from common resistance mutations such as EGFR C797S. MET amplification occurs in 66% (n = 6/9) of first-line osimertinib-treated patients, albeit spatially heterogeneous, often co-occurs with additional acquired focal copy-number amplifications and is associated with early progression. Noteworthy osimertinib-resistance mechanisms discovered include neuroendocrine differentiation without histologic transformation, PD-L1 , KRAS amplification, and ESR1-AKAP12 , MKRN1-BRAF fusions. The subclonal co-occurrence of acquired genomic alterations upon osimertinib resistance will likely require targeting multiple resistance mechanisms by combination therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2020.100007

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 180

Metadata

Authors
Roper, N., Brown, A.-L., Wei, J. S., Pack, S., Trindade, C., Kim, C., Restifo, O., Gao, S., Sindiri, S., Mehrabadi, F., El Meskini, R., Ohler, Z. W., Maity, T. K., Venugopalan, A., Cultraro, C. M., Akoth, E., Padiernos, E., Chen, H., Kesarwala, A., Smart, D. K., Nilubol, N., Rajan, A., Piotrowska, Z., Xi, L., Raffeld, M., Panchenko, A. R., Sahinalp, C., Hewitt, S., Hoang, C. D., Khan, J., & Guha, U.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2020-04
Volume
1
Issue
1
Pages
100007
ISSN
2666-3791 (ISSN-L)
OpenAlex
W3017413818
Cited by
180
References
10
FWCI
11.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. https://app.cochat.ai/papers/10.1016/j.xcrm.2020.100007
The paper
Roper, N., Brown, A.-L., Wei, J. S., Pack, S., Trindade, C., Kim, C., Restifo, O., Gao, S., Sindiri, S., Mehrabadi, F., El Meskini, R., Ohler, Z. W., Maity, T. K., Venugopalan, A., Cultraro, C. M., Akoth, E., Padiernos, E., Chen, H., Kesarwala, A., . . . Guha, U. (2020). Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2020.100007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.